Reuters logo
in 2 months
BRIEF-Coherus Biosciences prevails in '135 IPR decision
May 16, 2017 / 11:45 PM / in 2 months

BRIEF-Coherus Biosciences prevails in '135 IPR decision

1 Min Read

May 16 (Reuters) - Coherus Biosciences Inc:

* Coherus Biosciences prevails in '135 IPR decision

* Coherus Biosciences - patent trial, appeal board of U.S. Patent And Trademark Office ruled in favor of review of Abbvie's U.S. patent 8,889,135

* Coherus Biosciences-decision invalidates claims of patent that directed to method for treating rheumatoid arthritis by administering 40 MG of humira

* "Pleased that PTAB has decided to invalidate all claims of '135 patent" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below